- Home
- MAX vs AUTL Comparison
MAX vs AUTL Comparison
Compare MAX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAX | AUTL |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.8M | 433.8M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | MAX | AUTL |
|---|---|---|
| Price | $8.95 | $1.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $17.00 | $8.33 |
| AVG Volume (30 Days) | 640.2K | ★ 2.1M |
| Earning Date | 02-23-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,123,093,000.00 | $51,128,000.00 |
| Revenue This Year | $30.80 | $672.42 |
| Revenue Next Year | $8.49 | $84.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 64.86 | ★ 406.67 |
| 52 Week Low | $7.33 | $1.11 |
| 52 Week High | $13.92 | $2.70 |
Technical Indicators
Market Signals| Indicator | MAX | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 35.73 | 40.18 |
| Support Level | $8.33 | $1.31 |
| Resistance Level | $10.46 | $1.45 |
| Average True Range (ATR) | 0.49 | 0.07 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 41.25 | 18.37 |
Price Performance
Historical ComparisonAbout MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.